Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
CTI BioPharma Corp. ("CTI") (NASDAQ and MTA: CTIC) today announced that it intends to offer and sell, subject to market and other conditions, shares...
Cell Therapeutics, Inc. (CTI or the Company) (NASDAQ and MTA: CTIC), a biopharmaceutical company focused on acquiring, developing and bringing to...
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that management will present at the Jefferies 2014 Global Healthcare Conference...
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the first quarter ended March 31, 2014. "In the first...
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the launch of PIXUVRI® (pixantrone), the first new treatment for adult patients...
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that it will report its first quarter 2014 financial results on Tuesday, April...
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that management will present at the ROTH Capital Partners 26th Annual Conference ...
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of a Phase 3 clinical trial, known as PERSIST-2, which will...
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that Karen Ignagni has been appointed a Director of CTI, effective immediately....
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of an international cooperative group Phase 2 clinical trial of...
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the Gynecologic Oncology Group (GOG) informed CTI that it has completed...
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced a corporate update for 2014 in addition to an overview of recent progress for...
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that it has reached an agreement with Novartis to reacquire rights to two...
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported that the National Institute for Health and Care Excellence (NICE), the...
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that it has received notification from the U.S. Food and Drug Administration...
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that CTI has received the remaining $5 million from Hercules Technology Growth...
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced promising interim results from an investigator-initiated Phase 2 clinical trial...
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced results from an integrated analysis of data from two completed Phase 2 trials of ...
Cell Therapeutics, Inc. (CTI) (NASDAQ und MTA: CTIC) gaben heute bekannt, dass sie sich mit dem GKV Spitzenverband über den Preis von PIXUVRI®...
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that it concluded an agreement with the National Association of Statutory Health ...
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that it has received a $5 million milestone payment from Teva Pharmaceutical...
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that management will present at the following upcoming investor conferences....
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that members of management will host a conference call today, Friday, November...
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the upcoming presentations of data highlighting pacritinib, a novel, oral...
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the third quarter and nine months ended September 30, 2013. ...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.